- Home
- KALA vs CVKD Comparison
KALA vs CVKD Comparison
Compare KALA & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- CVKD
- Stock Information
- Founded
- KALA 2009
- CVKD 2022
- Country
- KALA United States
- CVKD United States
- Employees
- KALA N/A
- CVKD N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- KALA Health Care
- CVKD Health Care
- Exchange
- KALA Nasdaq
- CVKD Nasdaq
- Market Cap
- KALA 26.2M
- CVKD 29.5M
- IPO Year
- KALA 2017
- CVKD 2023
- Fundamental
- Price
- KALA $5.10
- CVKD $12.80
- Analyst Decision
- KALA Strong Buy
- CVKD Strong Buy
- Analyst Count
- KALA 3
- CVKD 1
- Target Price
- KALA $14.00
- CVKD $32.00
- AVG Volume (30 Days)
- KALA 71.3K
- CVKD 32.3K
- Earning Date
- KALA 08-05-2025
- CVKD 08-06-2025
- Dividend Yield
- KALA N/A
- CVKD N/A
- EPS Growth
- KALA N/A
- CVKD N/A
- EPS
- KALA N/A
- CVKD N/A
- Revenue
- KALA N/A
- CVKD N/A
- Revenue This Year
- KALA N/A
- CVKD N/A
- Revenue Next Year
- KALA N/A
- CVKD N/A
- P/E Ratio
- KALA N/A
- CVKD N/A
- Revenue Growth
- KALA N/A
- CVKD N/A
- 52 Week Low
- KALA $2.92
- CVKD $5.70
- 52 Week High
- KALA $11.20
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- KALA 62.32
- CVKD 49.60
- Support Level
- KALA $4.36
- CVKD $11.00
- Resistance Level
- KALA $5.90
- CVKD $13.71
- Average True Range (ATR)
- KALA 0.50
- CVKD 1.14
- MACD
- KALA 0.07
- CVKD 0.10
- Stochastic Oscillator
- KALA 61.50
- CVKD 63.54
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.